From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
TREM2-IN-1 (OPA) is a TREM2 inhibitor derived from oxaliplatin and artesunate. TREM2-IN-1 can relieves immunosuppressive tumor microenvironment and enhancing chemical anticancer efficiency. TREM2-IN-1 deters the tumor growth in mice models bearing MC38 colorectal tumor by reducing the number of CD206 + and CX3CR1 + immunosuppressive macrophages. TREM2-IN-1 also promotes the expansion and infiltration of immunostimulatory dendritic, cytotoxic T and natural killer cells .
TREM2 agonist-3 (Compound 4i) is a TREM2 agonist, with a KD value of 19.0 µM. TREM2 agonist-3 shows a KD value of 39.8 µM for TREM1. TREM2 agonist-3 induces an increase in phospho-SYK levels. TREM2 agonist-3 can be used in the research of neurodegenerative diseases and other diseases involving TREM2 dysfunction .
TREM2 agonist-4 (Compound 4a) is a TREM2 agonist with a Kd value of 45.9 μM. TREM2 agonist-4 can activate downstream signaling pathways of TREM2 and enhance the phagocytic function of microglia. TREM2 agonist-4 can be used in the research of neurodegenerative diseases such as Alzheimer's disease .
Trem2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Trem2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Trem1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Trem1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
TREM2 Human Pre-designed siRNA Set A contains three designed siRNAs for TREM2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Trem1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Trem1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Trem2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Trem2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
TREM1 Human Pre-designed siRNA Set A contains three designed siRNAs for TREM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody that targets TREM2. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
VJDT is a TREM1 inhibitor that can effectively block TREM1 signaling. VJDT inhibits tumor cell proliferation and migration and induces cell cycle arrest. VJDT has immunomodulatory and antitumor activities, and can be used for the research of tumors such as melanoma .
LQEEDAGEYGCMVDGAR, a 17-aa peptide, is a TREM-1 inhibitor. LQEEDAGEYGCMVDGAR shows anti-inflammatory effects that can reduce the secretion of pro-inflammatory cytokines induced by Lipopolysaccharides (HY-D1056) (LPS). LQEEDAGEYGCMVDGAR can be used for the study of sepsis .
DNL-919 (TAK-920) is a human IgG1 monoclonal antibody (mAb) targeting TREM-2. DNL-919 can be used in Alzheimer's disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
EOS006215 is a humanized monoclonal antibody inhibitor targeting TREM-2. EOS006215 reprograms TREM2 + macrophages, significantly blocks their pleiotropic pro-tumoral functions and overcomes resistance. EOS215 decreases metastasis burden in orthotopic 4T1 triple negative breast cancer mice model and significantly inhibits tumor growth in anti-PD-1 resistant mice model. EOS006215 can be used to study advanced malignant solid neoplasm, such as triple negative breast cancer (TNBC) .
Aurothiomalate (disodium) is a TRPA1 inhibitor. Aurothiomalate (disodium) inhibits NF-κB activation and iNOS expression. Aurothiomalate (disodium) promotes M2 transformation of macrophages and increases the expression of TREM-2 and arginase-1. Aurothiomalate (disodium) can be used in the study of liver fibrosis/cirrhosis and arthritis .
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .
Nangibotide (LR12) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide inhibits Apoptosis. Nangibotide reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .
Nangibotide TFA (LR12 TFA) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide TFA inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide TFA inhibits Apoptosis. Nangibotide TFA reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide TFA can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .
Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting radioligand for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography . NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Cyclocreatine- 13C3 is the 13C-labeled Cyclocreatine (HY-W017540). Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
PY314 is a humanized antibody expressed in CHO, targeting TREM2. PY314 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for PY314 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
EP4 receptor antagonist 7 (Compound 14) is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 with an IC50 value of 1.1 nM. EP4 receptor antagonist 7 inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC50 value of 0.9 nM. EP4 receptor antagonist 7 decreases PGE2-induced expression of mRNA encoding IL-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1), in RAW 264.7 macrophages. EP4 receptor antagonist 7 combined with an anti-PD-1 antibody inhibits tumor growth and increases infiltration of CD 8+ T cells into tumors in a CT26 murine colon cancer model .
TREM-1 inhibitory peptide GF9 (Human TREM-1(213-221)) is a ligand‐independent TREM‐1 inhibitory nonapeptide GF9 that can blunt excessive inflammation caused by rheumatoid arthritis (RA) .
TREM-1 inhibitory peptide M3 is a ligand-dependent TREM-1 antagonist. TREM-1 inhibitory peptide M3 can inhibit systemic and pulmonary pro-inflammatory cytokine and chemokine production and attenuate acute lung injury .
Mouse TREM-1 SCHOOL peptide (Mouse TREM-1(213-221), GF9) targets interactions between TREM-1 and its signaling partner DAP-12, and inhibits TREM-1 signaling. Mouse TREM-1 SCHOOL peptide has antitumor effect .
IA9 (human TREM-2 182-190) is a TREM-2 inhibitor , and can diminish release of proinflammatory cytokines and dramatically suppressed joint inflammation and damage in collagen-Induced Arthritis (CIA) mice model .
IA9 TFA (human TREM-2 182-190 TFA) is a TREM-2 inhibitor , and can diminish release of proinflammatory cytokines and dramatically suppressed joint inflammation and damage in collagen-Induced Arthritis (CIA) mice model .
LP17 (LQVTDSGLYRCVIYHPP) is a BBB-penetrable triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LP17 substantially alleviates ischemia-induced infarction and neuronal injury. LP17 can get access into brain and block TREM-1 .
LP17 (LQVTDSGLYRCVIYHPP) TFA is a BBB-penetrable triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LP17 TFA substantially alleviates ischemia-induced infarction and neuronal injury. LP17 TFA can get access into brain and block TREM-1 .
LQEEDAGEYGCMVDGAR, a 17-aa peptide, is a TREM-1 inhibitor. LQEEDAGEYGCMVDGAR shows anti-inflammatory effects that can reduce the secretion of pro-inflammatory cytokines induced by Lipopolysaccharides (HY-D1056) (LPS). LQEEDAGEYGCMVDGAR can be used for the study of sepsis .
Nangibotide (LR12) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide inhibits Apoptosis. Nangibotide reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .
Nangibotide TFA (LR12 TFA) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide TFA inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide TFA inhibits Apoptosis. Nangibotide TFA reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide TFA can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting radioligand for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography . NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody that targets TREM2. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
PY159 is a humanized antibody expressed in CHO cells, targeting TREM1/CD354. PY159 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for PY159 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .
PY314 is a humanized antibody expressed in CHO, targeting TREM2. PY314 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for PY314 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
DNL-919 (TAK-920) is a human IgG1 monoclonal antibody (mAb) targeting TREM-2. DNL-919 can be used in Alzheimer's disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
EOS006215 is a humanized monoclonal antibody inhibitor targeting TREM-2. EOS006215 reprograms TREM2 + macrophages, significantly blocks their pleiotropic pro-tumoral functions and overcomes resistance. EOS215 decreases metastasis burden in orthotopic 4T1 triple negative breast cancer mice model and significantly inhibits tumor growth in anti-PD-1 resistant mice model. EOS006215 can be used to study advanced malignant solid neoplasm, such as triple negative breast cancer (TNBC) .
TREM-2 Protein is a receptor for amyloid beta protein 42, lipoprotein particles, and apolipoprotein. TREM-2 Protein is involved in cell proliferation and apoptosis through Wnt/β, MTOR, PI3K and NF-kappa-B signaling pathways. TREM-2 Protein is expressed by macrophages, immature monocyte-derived dendritic cells, osteoclasts, and microglia to activate the immune response. TREM-2 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived TREM-2 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
TREM-2 protein forms a signaling complex with TYROBP, activates cells upon ligand binding, and acts as a receptor for amyloid beta, lipoproteins, and apolipoproteins. It promotes their uptake by microglia, triggering activation, proliferation, migration, apoptosis and cytokine expression. TREM-2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived TREM-2 protein, expressed by HEK293 , with C-6*His labeled tag.
The TREM-1 protein is a cell surface receptor that critically regulates innate and adaptive immunity by enhancing inflammatory responses. TREM-1 plays a crucial role in acute and chronic inflammatory diseases, acting as a decoy receptor to balance its pro-inflammatory effects. TREM-1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived TREM-1 protein, expressed by HEK293 , with C-8*His labeled tag.
The TREM-1 protein is a key cell surface receptor that amplifies inflammatory responses in innate and adaptive immunity. Ligands such as PGLYRP1, HMGB1 or HSP70 activate TREM-1, leading to multimerization and complex formation with TYROBP/DAP12. TREM-1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived TREM-1 protein, expressed by HEK293 , with C-6*His labeled tag.
TREM-2 Protein is a receptor for amyloid beta protein 42, lipoprotein particles, and apolipoprotein. TREM-2 Protein is involved in cell proliferation and apoptosis through Wnt/β, MTOR, PI3K and NF-kappa-B signaling pathways. TREM-2 Protein is expressed by macrophages, immature monocyte-derived dendritic cells, osteoclasts, and microglia to activate the immune response. TREM-2 Protein, Human (HEK293, His) is the recombinant human-derived TREM-2 protein, expressed by HEK293 , with C-6*His labeled tag.
The TREM-1 protein is a cell surface receptor that critically regulates innate and adaptive immunity by enhancing inflammatory responses. TREM-1 plays a crucial role in acute and chronic inflammatory diseases, acting as a decoy receptor to balance its pro-inflammatory effects. TREM-1 Protein, Human (HEK293, His) is the recombinant human-derived TREM-1 protein, expressed by HEK293 , with C-6*His labeled tag.
TREM-2 protein forms a signaling complex with TYROBP, activates cells upon ligand binding, and acts as a receptor for amyloid beta, lipoproteins, and apolipoproteins. It promotes their uptake by microglia, triggering activation, proliferation, migration, apoptosis and cytokine expression. TREM-2 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived TREM-2 protein, expressed by HEK293 , with C-6*His labeled tag.
TREML2 protein acts as a cell surface receptor for SEMA6A and affects key intercellular signaling in cerebellar development. It regulates granule cell migration, coordinates actin cytoskeletal reorganization, and contributes significantly to axonal guidance in the central nervous system. TREML2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived TREML2 protein, expressed by HEK293 , with C-6*His labeled tag.
TREML2 protein acts as a cell surface receptor, interacting with CD276 on T-cells to enhance T-cell activation and modulate immune responses, particularly in regulating T-cell activation during immune reactions. TREML2 Protein, Human (HEK293, Fc) is the recombinant human-derived TREML2 protein, expressed by HEK293 , with C-hFc labeled tag.
TREML1 (triggering receptor expressed on myeloid cells, like 1) is a cell surface receptor that may play a role in innate and adaptive immune responses. When phosphorylated, TREML1 interacts with the proteins PTPN6 and PTPN11, suggesting that it may be involved in regulating signaling pathways related to immune processes. TREML1 Protein, Human (147a.a, HEK293, His) is the recombinant human-derived TREML1 protein, expressed by HEK293 , with C-6*His labeled tag.
TREML1 is a trigger receptor 1 expressed on myeloid cells that activates myeloid cells via the adaptor protein DAP12. TREML1 promotes microglial phagocytosis of Aβ and is associated with the immune response to AD. TREML1 Protein, Mouse (HEK293, hFc) is the recombinant mouse-derived TREML1 protein, expressed by HEK293 , with C-hFc labeled tag.
TREML1 is a trigger receptor 1 expressed on myeloid cells that activates myeloid cells via the adaptor protein DAP12. TREML1 promotes microglial phagocytosis of Aβ and is associated with the immune response to AD. TREML1 Protein, Human (147a.a, HEK293, hFc) is the recombinant human-derived TREML1 protein, expressed by HEK293 , with C-hFc labeled tag.
CD300LB Protein, an activating immune receptor, engages in immune modulation by interacting with the ITAM-bearing adapter TYROBP and recruiting GRB2 independently. The interaction with TYROBP enhances cell surface expression and activation properties. In the presence of FYN, CD300LB also interacts with GRB2, showcasing its multifaceted contribution to immune signaling pathways. CD300LB Protein, Human (HEK293, hFc) is the recombinant human-derived CD300LB protein, expressed by HEK293 , with C-hFc labeled tag.
CD300 antigen like family member; CD300 antigen-like family member F; CD300 molecule like family member f; CD300f; CD300LF; CLM; CLM-1; CLM1; CMRF35-like molecule 1; IGSF; IgSF13; Inhibitory receptor IREM1; IREM; IREM-1; IREM1; Nepmucin; NK inhibitory receptor; NKIR; TREM
The CD300LF protein acts as a multifunctional immunomodulator, acting as an inhibitory receptor on myeloid cells and mast cells. It plays a vital role in immune homeostasis by actively regulating the phagocytosis of apoptotic cells by binding to phosphatidylserine. CD300LF Protein, Human (His) is the recombinant human-derived CD300LF protein, expressed by E. coli , with N-6*His labeled tag.
The CLM9/CD300g protein is known as a receptor and is thought to be involved in mediating L-selectin-dependent lymphocyte rolling. This protein exhibits calcium-dependent binding to SELL (L-selectin ligand), indicating its ability to interact with lymphocytes and potentially influence lymphocyte-related processes. CLM9/CD300g Protein, Human (HEK293, His) is the recombinant human-derived CLM9/CD300g protein, expressed by HEK293 , with C-6*His labeled tag.
The CLM9/CD300g protein is known as a receptor and is thought to be involved in mediating L-selectin-dependent lymphocyte rolling. This protein exhibits calcium-dependent binding to SELL (L-selectin ligand), indicating its ability to interact with lymphocytes and potentially influence lymphocyte-related processes. CLM9/CD300g Protein, Human (HEK293) is the recombinant human-derived CLM9/CD300g protein, expressed by HEK293 , with tag free.
The CLM9/CD300g protein is known as a receptor and is thought to be involved in mediating L-selectin-dependent lymphocyte rolling. This protein exhibits calcium-dependent binding to SELL (L-selectin ligand), indicating its ability to interact with lymphocytes and potentially influence lymphocyte-related processes. CLM9/CD300g Protein, Rat (HEK293, His) is the recombinant rat-derived CLM9/CD300g protein, expressed by HEK293 , with C-His labeled tag.
The CLM9/CD300g protein is known as a receptor and is thought to be involved in mediating L-selectin-dependent lymphocyte rolling. This protein exhibits calcium-dependent binding to SELL (L-selectin ligand), indicating its ability to interact with lymphocytes and potentially influence lymphocyte-related processes. CLM9/CD300g Protein, Human (HEK293, Fc) is the recombinant human-derived CLM9/CD300g protein, expressed by HEK293 , with C-hFc labeled tag.
The CD300LF protein, also known as DEC-205/CD205, directs antigens to the antigen-processing compartment. It inhibits myeloid cells and mast cells and promotes phagocytosis of apoptotic cells. CD300LF Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CD300LF protein, expressed by HEK293 , with C-mFc labeled tag.
Cyclocreatine- 13C3 is the 13C-labeled Cyclocreatine (HY-W017540). Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
TREM2 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 25 kDa, targeting to TREM2. It can be used for WB,IHC-P,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.
CD354 Antibody (YA4511) is a mouse-derived and non-conjugated IgG1 antibody, targeting to CD354. It can be applicated for WB, FC, ELISA assays, in the background of human, rat, monkey.
Trem2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Trem2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Trem1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Trem1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
TREM2 Human Pre-designed siRNA Set A contains three designed siRNAs for TREM2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Trem1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Trem1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Trem2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Trem2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
TREM1 Human Pre-designed siRNA Set A contains three designed siRNAs for TREM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
